LumiraDx Receives Approval for its COVID-19 Antigen Test for use in India

  • Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19  

  • LumiraDx’s microfluidic technology and innovative Point of Care (POC) Platform supports a broad menu of tests with lab-comparable performance, at a low cost, with results available in minutes


Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by

Continue Reading